The Federal Government's Therapeutic Goods Act provides the legislative basis on which control of drugs and medical devices can be structured. When, in the late 1970s, for the first time, expenditure on devices in Australia exceeded that on drugs, interest in the area of control of devices was aroused. A mechanism for the regulation of pharmaceuticals, the Australian Drug Evaluation Committee (ADEC), was already in place, However, there have been some problems in drug regulation, leading to friction between ADEC and industry and some dissatisfaction among members of the medical profession. In order to minimise similar difficulties in the device field, the Government and Health Department have adopted a different constitution, philosophy and modus operandi in setting up the Therapeutic Device Evaluation Committee (TDEC).
Even the most rabid consumer activist would be obliged to admit that Australia lacks the human resources, to say nothing of the funds, to enable detailed evaluation of the entire range of medical devices. A philosophy of priority allocation was therefore adopted early on, and five categories of 'designated devices' were identified, viz: infusion control devices, drug delivery systems, intraocular lenses, cardiac valves and pacemakers and intrauterine contraceptive devices.
Since February 2, 1987, devices in these categories have been subject to evaluation before approval is given for marketing. The importer and/or manufacturer is required to submit data in a prescribed format to the Secretary of the Department of Health. This list will be changed in response to experience and need.
All devices on sale prior to February 2 are required to be registered, and their approval has been automatic. After that date, registration is still required, but only in the five designated categories is evaluation obligatory. However, mechanisms do exist' to deal with devices which prove unsatisfactory in service or about which serious concern might exist (see below).
For over twelve months, the Medical Devices A device may be approved for sale or clinical trial, and unless it is in one of the five designated categories, will not usually require evaluation. However, there is discretion under the Act to require evaluation of any device, and the five . categories themselves are by no means permanent. Flexibility therefore exists whereby resources can be deployed where the need appears greatest.
A mechanism of hazard reporting is in the process of development. It depends on feedback from users in the field as well as Departmental scrutiny of international literature and bulletins. Any device which is reported as defective, and which on thorough investigation proves hazardous can be subjected to a recall mechanism, which in turn can be lifted following modifications or retrofitting, or remain in force if the defect proves incurable. Care is taken to ensure that devices are not unreasonably stigmatised as a result of user error.
The process of evaluation will not depend only on resources indigenous to Australia, but will draw on overseas evaluations and experience. To this end, the Department of Health is exploring both formal and informal means of facilitating an exchange of information between countries with similar systems, by means of which duplication of effort as well as costly delays may be avoided. The committee structure of TDEC will also make an important contribution to the evaluation process.
Unlike ADEC, TDEC has deliberately been established on a multi disciplinary basis, and also Anaesthesia and Intensil>e Care, Vol. 16, No. I, February, 1988 includes an industry representative who is a chemical engineer. Professional membership at this time includes persons from the disciplines of anaesthesia, biomedical engineering, intensive care, epidemiology and surgery (cardiothoracic). Supporting the committee is a large reserve of professionals with specific expertise in such areas as ophthalmology, cardiology, urology and orthopaedics. From among these experts, both individuals and panels can be mobilised to make available the experience of persons who are users of the device (or class of device) under evaluation. TDEC meets quarterly, but mechanisms exist to deal more rapidly with problems.
The first two issues of Therapeutic Devices Bulletin have appeared. Initial distribution was widespread, and the Department of Health will continue to circulate the Bulletin gratis to those respondents who indicate a desire to remain on its mailing list. Included in these issues were Hazard Notification forms by which TDEC hopes to be alerted to device problems of a significant nature. Professional organisations will be specifically targeted in a bid to ensure the effectiveness of the Hazard Alert mechanism.
The committee is aware of the difference between a device which carries the promise of relief AnaeSlhesia and Inlel/sire Care, Va!. 16, No. ], February, 1988 or cure of a hitherto recalcitrant and serious condition and one which does something clever without necessarily contributing a great deal to human comfort or welfare. Risks associated with the former which are quite acceptable in view of the potential benefit would be unreasonable in a device having only cosmetic or marginal value.
-An approach which allows rapid processing of clinically important devices is one cornerstone of TDEC policy. Another is the maintenance of close contact with the therapeutic community so that the committee is kept aware of important developments in special fields.
The impact ofTDEC remains to be seen, but the need for a mechanism for device regulation has now been recognised. Much will depend on the committee's ability to steer a reasonable course which retains the goodwill of device users, manufacturers and importers. These will forgive tough decisions, but not inefficiency. Users will presumably be happy if their special field is seen to be receiving appropriate priority. Above all, the committee must not lose sight of its primary responsibility to the ultimate consumers whose bodies wear the devices and whose taxes foot the bill.
